在日本患有扩散阶段小细胞肺癌的患者中,一线杜尔瓦卢马布加埃托波西德治疗
Eisuke Mochizuki1, Shun Matsuura1, Naoki Koshimizu1
1Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, Japan.
Cancer treatment and research communications
|August 1, 2025
概括
第一线埃托波西德,西斯普拉丁/卡博普拉丁和杜尔瓦卢马布在患有扩散阶段小细胞肺癌的日本患者中显示出有效性和良好的耐受性. 这种组合疗法被推作为该群体的标准护理.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于的化疗与免疫检查点抑制剂相结合,是针对扩散期小细胞肺癌 (ES-SCLC) 的新疗法.
- 第三阶段的CASPIAN研究显示,在ES-SCLC中,以托波/西斯普拉丁或卡博普拉丁 (EP) 以及杜尔瓦卢马布的治疗改善了生存率.
- 很少有日本患者被纳入先前的研究,因此需要对这一群体进行评估.
研究的目的:
- 评估一线埃托波/西斯普拉丁或卡博普拉丁 (EP) 加杜尔瓦卢马布在患有扩散阶段小细胞肺癌 (ES-SCLC) 的日本患者的疗效和安全性.
主要方法:
- 在八家日本医院对69名以前没有接受过治疗的ES-SCLC患者进行了回顾性研究 (2020年8月至2023年12月).
- 患者接受了四个周期的EP加上每3周一次的杜尔瓦卢马布,然后每4周一次的维护杜尔瓦卢马布.
- 主要终点:安全性. 二级终点:总生存率,无进展生存率,客观应答率和疾病控制率.
主要成果:
- 平均总生存时间为15.0个月;平均无进展生存时间为5.0个月.
- 客观应答率为75.4%;疾病控制率为92.8%.
- 3级以上的不良事件发生在72.5%的患者中;与免疫有关的不良事件发生在21.7%的患者中.
结论:
- 在现实环境中,一线EP加杜瓦卢马布在日本ES-SCLC患者中显示出有效性和耐受性.
- 结果与全球研究结果一致.
- 这种治疗方案被推为日本ES-SCLC患者的标准护理.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.1K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Vaccines
510
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
510
